Krebs Biochemicals & Industries (BSE: 524518) is a Visakhapatnam, Andhra Pradesh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹127 Cr, it ranks #3,039 by market cap among the 6,197 Indian listed companies on FinBizNet, and #65 of 86 in Medicinal Chemicals and Botanical Products. At ₹59.30 (as of 16 Nov 2026), the share price is 22.8% below its 52-week high of ₹76.85 and 54.7% above its 52-week low of ₹38.33. The share price is down 13.1% over one year and up 5.9% over three months.
| Current Price | ₹59.30 |
|---|---|
| Market Cap | ₹127 Cr |
| BSE Code | 524518 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | 10.96% |
| Return on Assets | -3.75% |
| 52-Week Range | ₹38.33 – ₹76.85 |
| 1-Year Price Change | -13.1% |
| 3-Month Price Change | +5.9% |
| Beta (1Y) | 0.88 |
| Dividend Yield | 0.00% |
| Headquarters | Visakhapatnam, Andhra Pradesh |
| Website | krebsbiochem.com |
| Revenue | ₹6 Cr |
|---|---|
| Net Profit | ₹-5 Cr |
| Net Margin | -93.3% |
| EPS (Basic) | ₹-2.50 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Krebs Biochemicals & Industries reported revenue of ₹6 Cr in Q2 FY27, up 38.8% from ₹4 Cr in Q2 FY26 and down 17.0% from ₹7 Cr in Q1 FY27. It posted a net loss of ₹5 Cr for the quarter, against a net loss of ₹6 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹4 Cr (Q2 FY26) to ₹7 Cr (Q3 FY26). The company reported a net loss in 7 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹6 Cr | −₹5 Cr | −93.3% |
| Q1 FY27 | ₹7 Cr | −₹2 Cr | −35.5% |
| Q4 FY26 | ₹7 Cr | −₹2 Cr | −34.4% |
| Q3 FY26 | ₹7 Cr | −₹3 Cr | −43.1% |
| Q2 FY26 | ₹4 Cr | −₹6 Cr | −147.2% |
| Q1 FY26 | ₹5 Cr | −₹5 Cr | −97.1% |
| Q4 FY25 | ₹6 Cr | −₹8 Cr | −135.6% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 72.74% of Krebs Biochemicals & Industries's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 64.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
1. Segment Adjustment-This segment manufactures active pharmaceutical ingredients. 2. Pharma-This segment produces potato crisps. It also engages in the manufacture and sale of sugar. 3. Food-This segment manufactures sugar. 4. Sugar-0
1. Pharma-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Krebs Biochemicals & Industries | ₹127 Cr | n/m | 10.96% | ₹6 Cr | -13.1% |
Listed by market capitalisation. Ratios are shown for context only.
Krebs Biochemicals & Industries is trading at ₹59.30, with a market capitalisation of ₹127 Cr.
Krebs Biochemicals & Industries operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Krebs Biochemicals & Industries has a return on equity of 10.96%.
Krebs Biochemicals & Industries is listed on the BSE under the scrip code 524518.
Krebs Biochemicals & Industries's share price is down 13.1% over one year and up 5.9% over three months. Its 52-week range is ₹38.33 to ₹76.85.
In Q2 FY27, Krebs Biochemicals & Industries reported revenue of ₹6 Cr and net profit of ₹-5 Cr, with basic EPS of ₹-2.5 (standalone, parsed from the company's exchange filing).
Krebs Biochemicals & Industries reported revenue of ₹6 Cr in Q2 FY27, up 38.8% from ₹4 Cr in Q2 FY26 and down 17.0% from ₹7 Cr in Q1 FY27.
Promoters held 72.74% of Krebs Biochemicals & Industries's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.